Clinical Data — Rodman & Renshaw Global Investment Conference 2009
24 slides from Clinical Data's conference presentation, Sep 9, 2009

Slide 1: Rodman & Renshaw Global Investment Conference September 9, 2009
1 Rodman & Renshaw Global Investment Conference September 9, 2009

Slide 2: Forward-Looking Statement
Forward-Looking Statement 2 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements a

Slide 3: Investment Opportunity
Investment Opportunity Clinical Data is a biotechnology company developing late-stage drugs that are first-in-class, best-in-category 3 Central Nervous System Cardiovascular Disease Oncology

Slide 4: Current Value Drivers
Current Value Drivers Two Phase III drugs: Vilazodone(tm): first-in-class dual acting serotonergic antidepressant Stedivaze(tm): potential best-in-class drug used as a vasodilator for cardiac stress testing Deep pipeline of drugs and biomarker candidates Genetic testing business for inherited cardia

Slide 5: Depression is Largest Segment of CNS Market
Depression is Largest Segment of CNS Market U.S. market continues to grow1 $12B annual sales 208M+ prescriptions Medical cost to treat depression is close to $30B annually2 Vilazodone relevant market SSRIs (i.e. Zoloft(r), Lexapro(r), Celexa(r), Prozac(r)) SNRIs (i.e. Cymbalta(r), Effexor(r)XR, Pris

Slide 6: New Options Needed in Treatment of Depression
New Options Needed in Treatment of Depression Majority of patients do not achieve success with 1st therapy1 Side effects are common, tolerability is a challenge Co-morbid conditions often require additional medications 40% of depressed patients have anxiety Patient compliance remains poor 6 1 STAR*D

Slide 7: Vilazodone for Treatment of Depression
Vilazodone for Treatment of Depression First-in-class antidepressant with a dual serotonergic mechanism of action SSRI 5HT1A Demonstrated superiority to placebo in 2 Phase III trials Well-tolerated with low discontinuation rate Sexual function is similar to placebo as measured by validated scales Op

Slide 8: Requirements for NDA Submission
Requirements for NDA Submission FDA requires demonstration of: Acceptable risk/benefit ratio Statistical significance in two adequately powered controlled trials Robust results on multiple measures using multiple analytic methods (MADRS, HAMD, CGI) Safety in both acute and chronic administration Dat

Slide 9: 2nd Phase III Trial Confirms Superiority to Placebo
2nd Phase III Trial Confirms Superiority to Placebo 9 Least Squares Mean Change at Week 8 Least Squares Mean Change at Week 8 LS Mean Treatment Difference p-value 1st Phase III Vilazodone N = 198 Placebo N = 199 MADRS -12.9 -9.6 -3.2 0.001 HAMD17 -10.4 -8.6 -1.7 0.022 HAMA -6.5 -5.2 -1.4 0.031 2nd P

Slide 10: Adverse event comparison: Zoloft, Lexapro, Effexor XR and vilazodone
Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* AE Drug Placebo Nausea 26% 12% Diarrhea/ loose stools 18% 9% Somnolence 13% 6% Tremor 11% 3% Sweating Increased 8% 3% Ejaculation failure 7% <1% Dyspepsia 6% 3% Vilazodone Phase III Tria

Slide 11: Low Discontinuation Rates in Phase III Studies
Low Discontinuation Rates in Phase III Studies 11 1st Phase III Trial 1st Phase III Trial 2nd Phase III Trial 2nd Phase III Trial Vilazodone Placebo Vilazodone Placebo Enrolled 205 205 240 241 Discontinued 53 (25.9%) 51 (24.9%) 47 (19.6%) 46 (19.1%) Adverse Event 19 (9.3%) 10 (4.9%) 12 (5.1%) 4 (1.7

Slide 12: Sexual Dysfunction is Common in Depression
Sexual Dysfunction is Common in Depression 40 to 50% of depressed patients report sexual dysfunction1 Drug-induced SD is common with antidepressants Reliance on spontaneous reporting significantly underestimates incidence 65% of physicians felt lack of drug-induced SD was extremely important when ch

Slide 13: Vilazodone Impact on Overall Sexual Function Comparable to Placebo
13 Vilazodone Impact on Overall Sexual Function Comparable to Placebo in 2nd Phase III Trial 13 Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score

Slide 14: Depression Market is Highly Concentrated to Top Prescribers
Market Decile Number of Prescribers Minimum TRx Maximum TRx Average TRx Cum. % of Prescribers Cum. % of TRx 10 3,517 3,545 28,320 5,123 0.5% 10.0% 9 6,437 2,342 3,545 2,800 1.5% 20.0% 8 8,890 1,792 2,341 2,027 2.9% 30.0% 7 11,245 1,445 1,792 1,603 4.7% 40.0% 6 13,864 1,174 1,445 1,300 6.8% 50.0% 5 1

Slide 15: Depression Drugs Compete in Generic Market
Depression Drugs Compete in Generic Market 15 Quarterly Sales 2003 - 2008 SSRIs: Zoloft(r), Lexapro(r), Celexa(r) - SNRIs: Cymbalta(r), Effexor(r)XR, IMS HEALTH'S National Sales Perspective Celexa(r) goes generic (10/04) Zoloft(r) goes generic (7/06)

Slide 16: Vilazodone Addresses Unsatisfied Market
Vilazodone Addresses Unsatisfied Market Favorable physician acceptance in market research1 Received a 7/10 rating Over 60% would probably or definitely prescribe vilazodone Commercial preparations underway to maximize potential from product approval to first prescription Several approaches to commer

Slide 17: Stedivaze: Vasodilator for Cardiac Stress Testing
Stedivaze: Vasodilator for Cardiac Stress Testing U.S. market projected to be $800M in 20111 Potential best-in-class vasodilator Phase II data demonstrated: Improved tolerability over existing agents Rapid onset and offset of action Diagnostic accuracy Ease of use via fixed bolus dosing 17 1 AMR Mon

Slide 18: Stedivaze AE Profile is Better than Adenoscan in Phase II Trial
Stedivaze AE Profile is Better than Adenoscan in Phase II Trial Hendel et al AHA, 2005 *Safety population only. Incidence of AEs 5% or greater. 18 Dyspnea Chest Pain Dizziness Headache Flushing Hypotension Nausea 2° AV Block % with AEs Adenoscan 0 20 40 N = 124 Stedivaze (Apadenoson) 1.0 ^g/kg 2.0 ^

Slide 19: Stedivaze Clinical Development Program
Stedivaze Clinical Development Program Initiated Phase I studies in chronic obstructive pulmonary disease and asthma to demonstrate safety Marketed adenosine agonists carry a warning or are contra- indicated in patients with COPD and asthma Increased selectivity of Stedivaze may permit safe use in t

Slide 20: Therapeutics Pipeline
Therapeutics Pipeline Current Stage Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Novartis Confidential Partner Vilazodone(tm) Major Depression Stedivaze(tm) Cardiac Stress Testing ATL1222: Acute Inflammation ATL844: Diabetes / Asthma ATL313 : Ophthalmic Oncology Pain AVN316: On

Slide 21: Dx for Inherited Cardiac Conditions: FAMILION
Dx for Inherited Cardiac Conditions: FAMILION(r) Over 100% Growth Year Over Year* *Calendar Year 21 $0 $.5 $1 $1.5 $2 $2.5 2004 2005 2006 2007 2008 New Sales Force $ (Millions) $3 2009 $3.5 $4

Slide 22: Clinical Data (CLDA) Profile
Clinical Data (CLDA) Profile* 22 Revenue: $ 3.7M (3 mos.) $10.4M (Year ended 3/31/09) Cash & Marketable Securities: $52.4M Debt: $51.7M** Shares Outstanding: 23.5M Insider Ownership: ~ 50% Substantially all shares purchased *As of 6/30/09 unless otherwise indicated **Net of unamortized discount of $

Slide 23: Upcoming Events
Upcoming Events Submit vilazodone NDA to the FDA and continue preparations for commercialization Complete Phase I studies for Stedivaze in COPD and asthma; start Phase III program in 4Q calendar 2009 Establish partnerships for other preclinical programs 23

Slide 24: Thank You
- — 7 r if = og 4 Fiom Targeted Science y GF ~ to Beiter Healthcare™ & & L = eC , Thank You
Source: SEC EDGAR · 8-K filed Sep 9, 2009
More decks from Clinical Data Inc
J. P. Morgan Healthcare Conference 201127 slides · Jan 12, 2011
Technical Presentation (May 2010)10 slides · May 25, 2010
BMO Capital Markets Focus on Healthcare Conference 200930 slides · Aug 5, 2009
Fifth Annual Noble Financial Equity Conference 200923 slides · Jun 9, 2009
Investor Presentation (January 2009)25 slides · Jan 12, 2009
BMO Capital Markets Focus On Healthcare Conference 200833 slides · Aug 5, 2008